与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ 8-K - Current report Filed: 2018-01-08 AccNo: 0001104659-18-001136 Size: 5 MBItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2018-01-05 AccNo: 0001104659-18-000981 Size: 38 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2018-01-05 AccNo: 0001104659-18-000884 Size: 29 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接
$井寺制药(IDRA)$ 内部交易: 2017-12-15,10% Owner,Pillar Invest Corp ,卖出,33830普通股, $1.91
$井寺制药(IDRA)$ 内部交易: 2017-12-14,10% Owner,Pillar Invest Corp ,卖出,1166170普通股, $2.00
$井寺制药(IDRA)$ 内部交易: 2017-12-13,10% Owner,Pillar Invest Corp ,卖出,1100000普通股, $1.93
$井寺制药(IDRA)$ DEF 14A - Other definitive proxy statements Filed: 2017-11-17 AccNo: 0001047469-17-007164 Size: 875 KB 网页链接
$井寺制药(IDRA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2017-11-06 AccNo: 0001558370-17-008228 Size: 4 MB 网页链接
$井寺制药(IDRA)$ PRE 14A - Other preliminary proxy statements Filed: 2017-10-31 AccNo: 0001047469-17-006677 Size: 1 MB 网页链接
$井寺制药(IDRA)$ 内部交易: 2017-10-26,Director,BAKER BROS. ADVISORS LP ,买入,8000000普通股, $1.50